Delivery Order 75F40121D00007-75F40124F19007
- Not listed
- This federal contract award to Pacific Biosciences of California, Inc. is a delivery order under an Indefinite Delivery Indefinite Quantity (IDIQ) contract #75F40121D00007 with the Food and Drug Administration (FDA). The purpose is to purchase specific supplies and reagents for the PacBio Sequel IIe long-read DNA/RNA sequencer. The award is for a firm fixed-price of $46,341.66, with a period of performance through May 30, 2025. Pacific Biosciences is the original equipment manufacturer for the...
- The U.S. Food and Drug Administration awarded a Firm Fixed Price Purchase Order contract to Pacific Biosciences of California, Inc., a small business manufacturer, for the delivery of PacBio Revio sequencing reagent kits or equal products. The $48,715.20 contract has a completion date of September 30, 2024 and will support research at the FDA's National Center for Toxicological Research. This award is associated with a larger $1 million single-award Indefinite Delivery Indefinite Quantity (IDIQ)...
- This federal contract award is for the procurement of PacBio Sequel II and IIe system reagents and consumables by the Food and Drug Administration (FDA). The $15,713.10 firm-fixed price contract was awarded on July 23, 2024 to Pacific Biosciences of California, Inc., a leading manufacturer of high-throughput, long-read DNA sequencing platforms and associated products. The contract does not have a set-aside designation. Pacific Biosciences holds two relevant Indefinite Delivery Indefinite...
- This federal contract award to Pacific Biosciences of California, Inc. (PacBio) provides for the delivery of a PacBio RS DNA sequencing system with a 12-month service contract. The $998,000.00 firm fixed price contract was awarded by the Food and Drug Administration (FDA), a civilian agency, without the use of a set-aside. PacBio is the original equipment manufacturer for the PacBio Sequel and Sequel II sequencing platforms, which are in high demand across federal agencies for genomic research...
- The U.S. Food and Drug Administration awarded a $736,000 firm fixed-price definitive contract to Pacific Biosciences of California, Inc. for a real-time sequencer system with four one-year post-warranty maintenance option periods. The contract, awarded on September 3, 2019, with an ultimate completion date of December 11, 2024, is designated as a Total Small Business set-aside. Pacific Biosciences, a leading biotechnology company specializing in advanced DNA and RNA sequencing technologies, will...
- This contract award to Pacific Biosciences of California, Inc., a small business manufacturer, is for the provision of high-throughput, long-read DNA sequencing systems and associated consumables to the U.S. Food and Drug Administration (FDA). The $83,644 firm fixed-price purchase order has an ultimate completion date of October 14, 2015. Pacific Biosciences is the original equipment manufacturer for their proprietary single molecule, real-time (SMRT) sequencing technology, which is utilized...
- The Food and Drug Administration (FDA) awarded a $336,000 firm fixed-price purchase order to Pacific Biosciences of California, Inc. on August 21, 2015, for Part Number 100-236-400, a standard PacBio service contract with a base period and four option years. The contract was completed on July 22, 2019, with performance undertaken at the contractor's facility in Menlo Park, California. No set-aside designation was applied to this award. Pacific Biosciences is a leading biotechnology company...
- This contract award is for the purchase of reagents and supplies from Pacific Biosciences of California, Inc. by the U.S. Department of Health and Human Services' Food and Drug Administration. The items include PacBio's proprietary single molecule real-time (SMRT) sequencing consumables such as template prep kits, binding kits, and SMRT cells to support the agency's genomic research initiatives. The $46,548 firm-fixed price delivery order does not utilize a set-aside program. Pacific Biosciences...
- This is a delivery order awarded to Pacific Biosciences of California, Inc., a manufacturer of DNA/RNA sequencing systems and associated consumables, by the Department of Health and Human Services' Food and Drug Administration. The $69,567.00 firm-fixed-price order is for the provision of sequencing reagents, kits, and consumables to support the agency's genomic research initiatives. Pacific Biosciences has extensive experience providing specialized sequencing equipment and supplies to various...
- The Department of Health and Human Services Food and Drug Administration awarded a $51,193.93 purchase order to Pacific Biosciences of California, Inc. for sequencing supplies. The firm fixed price contract runs from August 23, 2023 to February 19, 2024 and will be performed by Pacific Biosciences in West Menlo Park, California. The original solicitation sought sequencing supplies as described in Combined Synopsis Solicitation 75F40123Q-117934 to support the FDA's evaluation of new sequencing...
- 75F40121D00007Indefinite Delivery Contract
- 75F40121D00007-75F40124F19007Delivery Order
The U.S. Food and Drug Administration (FDA) has awarded a $39,657.00 firm fixed-price delivery order to Pacific Biosciences of California, Inc. (PacBio) under the company's existing $1 million Indefinite Delivery, Indefinite Quantity (IDIQ) contract with the agency. This delivery order is for the purchase of specific supplies and reagents to support the agency's use of PacBio's Sequel IIe long-read DNA/RNA sequencing platform. The award, made without a set-aside designation, is the latest task order issued under PacBio's IDIQ contract with the FDA, which was initially awarded in March 2021 to provide sequencing consumables and related services through March 2025. PacBio is a leading manufacturer of advanced DNA sequencing systems and associated products, which are widely utilized across federal research programs in areas such as agriculture, infectious diseases, and biotechnology.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.7k | 7/25/24 |